Drug Search Results
More Filters [+]

EYS-611

Alternative Names: eys-611, eys 611, eys611
Latest Update: 2023-04-24
Latest Update Note: Clinical Trial Update

Product Description

EYS611, a DNA plasmid that encodes for the human transferrin protein, to benefit patients diagnosed with retinitis pigmentosa (RP), as well as other degenerative retinal diseases, including late stage, dry age-related macular degeneration and glaucoma. (Sourced from: https://www.eyevensys.com/eyevensys-receives-fda-orphan-drug-designation-for-eys611-for-treatment-of-retinitis-pigmentosa/)

Mechanisms of Action: Gene Therapy,Transferrin

Novel Mechanism: Yes

Modality: Gene Therapy

Route of Administration: Injection

FDA Designation: Orphan Drug - Retinitis Pigmentosa|Retinitis *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Eyevensys
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for EYS-611

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 0: Retinitis Pigmentosa

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events